Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead 1Q Net Slips 32% On Higher Expenses, Weaker Margins

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 10:54pm CET

Gilead Sciences Inc. (>> Gilead Sciences, Inc.) first-quarter earnings slid 32% as the biopharmaceutical company reported higher expenses and weaker margins, though adjusted profits improved.

Product sales, which generate the majority of the company's revenue, have been rising steadily in recent quarters. In the latest period, product sales rose 19%. Sales of antiviral products, its dominant revenue stream, increased 18 as HIV drugs Atripla and Truvada saw sales gains of 19% and 13%, respectively.

The company also receives royalties for Tamiflu from Roche Holding AG (RHHBY, ROG.VX). Royalty, contract and other revenue from collaborations were also up 19% last quarter.

Lately, Gilead has been focusing on simplifying HIV therapy, a treatment market that it dominates. In December, U.S. regulators accepted Gilead's new drug application for its Quad combination HIV drug, which analysts view as a potential growth driver. The Food and Drug Administration in February also granted Truvada a priority-review schedule, advancing what could become the first treatment labeled for HIV prevention.

Earlier this year, Gilead bought Pharmasset Inc. for more than $11 billion in a deal expected to accelerate the development of treatments for hepatitis C, a hotly contested market. A key drug candidate it obtained with Pharmasset, GS-7977, suffered a setback in February as a majority of hepatitis-C patients in one arm of a clinical trial had a relapse, raising questions about the drug's potential.

In the latest quarter, Gilead posted a profit of $442 million, or 57 cents a share, down from $651.1 million, or 80 cents a share, a year earlier. Excluding acquisition-related expenses, restructuring and stock-based compensation, earnings rose to 91 cents from 87 cents.

Revenue gained 19% to $2.28 billion.

Analysts polled by Thomson Reuters had expected a profit of 93 cents a share and revenue of $2.2 billion.

Operating margin narrowed to 35.1% from 46.8% as total costs and expenses jumped 45%.

Shares were down 1.4% to $52 after-hours. Through the close, the stock is up 29% since the start of the year.

 
   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; [email protected] 

Stocks mentioned in the article : Gilead Sciences, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
12/15 GILEAD SCIENCES : Galapagos exercises co-promotion option for filgotinib with co..
12/14 GILEAD SCIENCES : Announces That John C. Martin, PhD Will Transition From Execut..
12/14 GILEAD SCIENCES : Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yes..
12/14 GILEAD SCIENCES : Kite Announces Data from ZUMA-3 Study of KTE-C19 in Adult Pati..
12/14 GILEAD SCIENCES : ex-dividend day
12/13 Celgene, Gilead, and Regeneron are On the Mend
12/13 GILEAD SCIENCES : Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Pati..
12/13 GILEAD SCIENCES : (GILD) Posts Updated Data on CAR-T Therapy Yescarta
12/12 GILEAD SCIENCES : adds to CAR-T assets with Cell Design Labs buyout
12/12 GILEAD SCIENCES : Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Pati..
More news
News from SeekingAlpha
12/16 Venture capital deals of the week
12/15 MY JOURNEY TO FINANCIAL INDEPENDENCE : 86-Stock November Portfolio Update - Buyi..
12/15 UPCOMING CONVERSATION WITH AN EXPERT : Highlights In CAR-T
12/15 Teva launches generic Viread in U.S.
12/14 Galapagos elects to co-promote filgotinib with Gilead in Europe
Financials ($)
Sales 2017 25 816 M
EBIT 2017 15 661 M
Net income 2017 10 511 M
Debt 2017 12 742 M
Yield 2017 2,80%
P/E ratio 2017 9,71
P/E ratio 2018 12,66
EV / Sales 2017 4,32x
EV / Sales 2018 4,89x
Capitalization 98 689 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 85,7 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES6.94%98 689
REGENERON PHARMACEUTICALS5.33%41 789
VERTEX PHARMACEUTICALS96.55%36 888
GENMAB-11.85%9 967
BLUEBIRD BIO INC199.68%8 385
EXELIXIS, INC.78.27%7 722